肿瘤浸润淋巴细胞(til): 30年研究的经验教训

Kristen M. Drescher , Henry T. Lynch
{"title":"肿瘤浸润淋巴细胞(til): 30年研究的经验教训","authors":"Kristen M. Drescher ,&nbsp;Henry T. Lynch","doi":"10.1016/j.cair.2005.03.002","DOIUrl":null,"url":null,"abstract":"<div><p><span>The interplay between tumor development and the host immune system, as well as the impact of the immune system on the tumor's metastatic potential<span> is incompletely defined. Almost 30 years ago, the identification of tumor infiltrating lymphocytes was reported, and represented great hope in cancer treatment. At that time, it was thought that patients whose tumors had high numbers of tumor infiltrating lymphocytes had a good prognosis, while patients with few or no tumor infiltrating lymphocytes had a poor prognosis. Work published since that seminal report has indicated that this viewpoint is overly simplistic. While infiltration of the tumor with lymphocytes may be one factor associated with a positive outcome, the milieu required for optimal functioning of the immune system is also defined by the presence of potent </span></span>antigen presenting cells<span><span>, immunostimulatory cytokines, and optimal surface molecule expression by both the tumor cells and the infiltrating lymphocytes. The complexities of these interactions are just beginning to be defined; a further difficulty that must be addressed in the development of cancer immunotherapy regimens is that various forms of cancer appear to have different immune system requirements. Failure of the host to achieve the optimal </span>tumor microenvironment<span><span> severely compromises the ability of the host to control tumor growth and metastases. Animal models of cancer, imperfect as they are, can provide investigators with model systems for manipulating the immune parameters of the tumor site within the host to determine its effect on disease outcome. While mouse models cannot fully mimic the processes observed in humans because of differences in surface molecule expression and signaling pathways between the species, they do provide investigators with a means to examine the mechanisms involved following </span>immunotherapy. This review will discuss some of the immune parameters studied in tumor infiltrating lymphocytes and how they have been associated with patient prognosis.</span></span></p></div>","PeriodicalId":89340,"journal":{"name":"Clinical and applied immunology reviews","volume":"5 3","pages":"Pages 149-166"},"PeriodicalIF":0.0000,"publicationDate":"2005-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.cair.2005.03.002","citationCount":"13","resultStr":"{\"title\":\"Tumor infiltrating lymphocytes (TILs): Lessons learned in 30 years of study\",\"authors\":\"Kristen M. Drescher ,&nbsp;Henry T. Lynch\",\"doi\":\"10.1016/j.cair.2005.03.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p><span>The interplay between tumor development and the host immune system, as well as the impact of the immune system on the tumor's metastatic potential<span> is incompletely defined. Almost 30 years ago, the identification of tumor infiltrating lymphocytes was reported, and represented great hope in cancer treatment. At that time, it was thought that patients whose tumors had high numbers of tumor infiltrating lymphocytes had a good prognosis, while patients with few or no tumor infiltrating lymphocytes had a poor prognosis. Work published since that seminal report has indicated that this viewpoint is overly simplistic. While infiltration of the tumor with lymphocytes may be one factor associated with a positive outcome, the milieu required for optimal functioning of the immune system is also defined by the presence of potent </span></span>antigen presenting cells<span><span>, immunostimulatory cytokines, and optimal surface molecule expression by both the tumor cells and the infiltrating lymphocytes. The complexities of these interactions are just beginning to be defined; a further difficulty that must be addressed in the development of cancer immunotherapy regimens is that various forms of cancer appear to have different immune system requirements. Failure of the host to achieve the optimal </span>tumor microenvironment<span><span> severely compromises the ability of the host to control tumor growth and metastases. Animal models of cancer, imperfect as they are, can provide investigators with model systems for manipulating the immune parameters of the tumor site within the host to determine its effect on disease outcome. While mouse models cannot fully mimic the processes observed in humans because of differences in surface molecule expression and signaling pathways between the species, they do provide investigators with a means to examine the mechanisms involved following </span>immunotherapy. This review will discuss some of the immune parameters studied in tumor infiltrating lymphocytes and how they have been associated with patient prognosis.</span></span></p></div>\",\"PeriodicalId\":89340,\"journal\":{\"name\":\"Clinical and applied immunology reviews\",\"volume\":\"5 3\",\"pages\":\"Pages 149-166\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2005-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.cair.2005.03.002\",\"citationCount\":\"13\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and applied immunology reviews\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1529104905000309\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and applied immunology reviews","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1529104905000309","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 13

摘要

肿瘤发展与宿主免疫系统之间的相互作用,以及免疫系统对肿瘤转移潜力的影响尚不完全清楚。大约30年前,肿瘤浸润淋巴细胞的鉴定被报道出来,在癌症治疗中代表了巨大的希望。当时认为肿瘤浸润淋巴细胞数量多的患者预后较好,肿瘤浸润淋巴细胞少或无的患者预后较差。自那份开创性报告以来发表的工作表明,这种观点过于简单化。虽然淋巴细胞浸润肿瘤可能是与阳性结果相关的一个因素,但免疫系统最佳功能所需的环境也取决于强效抗原呈递细胞、免疫刺激细胞因子的存在,以及肿瘤细胞和浸润淋巴细胞的最佳表面分子表达。这些相互作用的复杂性才刚刚开始被定义;在癌症免疫治疗方案的发展中必须解决的另一个困难是,不同形式的癌症似乎有不同的免疫系统需求。宿主不能达到最佳肿瘤微环境严重损害了宿主控制肿瘤生长和转移的能力。癌症动物模型虽然不完善,但可以为研究人员提供模型系统,用于操纵宿主肿瘤部位的免疫参数,以确定其对疾病结局的影响。虽然小鼠模型不能完全模拟在人类中观察到的过程,因为物种之间表面分子表达和信号通路的差异,但它们确实为研究人员提供了一种检查免疫治疗后涉及的机制的方法。本文将讨论肿瘤浸润淋巴细胞的一些免疫参数及其与患者预后的关系。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Tumor infiltrating lymphocytes (TILs): Lessons learned in 30 years of study

The interplay between tumor development and the host immune system, as well as the impact of the immune system on the tumor's metastatic potential is incompletely defined. Almost 30 years ago, the identification of tumor infiltrating lymphocytes was reported, and represented great hope in cancer treatment. At that time, it was thought that patients whose tumors had high numbers of tumor infiltrating lymphocytes had a good prognosis, while patients with few or no tumor infiltrating lymphocytes had a poor prognosis. Work published since that seminal report has indicated that this viewpoint is overly simplistic. While infiltration of the tumor with lymphocytes may be one factor associated with a positive outcome, the milieu required for optimal functioning of the immune system is also defined by the presence of potent antigen presenting cells, immunostimulatory cytokines, and optimal surface molecule expression by both the tumor cells and the infiltrating lymphocytes. The complexities of these interactions are just beginning to be defined; a further difficulty that must be addressed in the development of cancer immunotherapy regimens is that various forms of cancer appear to have different immune system requirements. Failure of the host to achieve the optimal tumor microenvironment severely compromises the ability of the host to control tumor growth and metastases. Animal models of cancer, imperfect as they are, can provide investigators with model systems for manipulating the immune parameters of the tumor site within the host to determine its effect on disease outcome. While mouse models cannot fully mimic the processes observed in humans because of differences in surface molecule expression and signaling pathways between the species, they do provide investigators with a means to examine the mechanisms involved following immunotherapy. This review will discuss some of the immune parameters studied in tumor infiltrating lymphocytes and how they have been associated with patient prognosis.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信